Last summer, the Vi Partners technology team led a pre-seed round in Morgen.so. We are delighted to partner with a ground breaking time management application built by a stellar team that has the ambition to transform how knowledge workers deal with their time, boost their productivity while improving their worklife balance and overall wellbeing.
Xeltis, a clinical stage medtech company developing living implants that enable the body to restore cardiovascular function, announces that it has raised €32 million in a Series D2 equity fundraise.
It is a clear sign a New Year has started when you get to read all the market reports from the past year. It is a great time to reflect how 2022 went so quickly. We see no need to repeat the global news cycle or the generic takes on how the market went, others are doing this very well. From our perspective we look at a specific segment of the market and would like to share how we look at what 2022 gave us.
The Swiss AI start-up Acodis closed a CHF 6m financing round from existing and new investors. Acodis, the leading Intelligent Document Processing (IDP) platform, raised CHF 6 million in a Series A funding round led by Hi Inov and VI Partners. The new funds will be used to further expand Acodis' position as the leading Document Processing Platform for the Pharma and Health sector.
A great start to the year as VI Partners welcomes Clara Millan as Operations and Finance Manager.
Pierrick co-founded Picterra, the machine-learning geospatial imagery service, six years ago. Back then he boarded the rollercoaster of entrepreneurship and has a cool and calm acceptance of the uncertainty that the ride brings.
Xeltis announced the initiation of a pivotal trial for the first-ever restorative synthetic hemodialysis access grafts, aXess. The first two patients have been successfully implanted, as part of the AXESS European pivotal trial at AZ Sint-Jan Brugge-Oostende AV in Bruges, Belgium by vascular surgeon Dr. Jan De Letter and discharged from hospital.
Sibylla Biotech today announced the successful close of its €23 million Series A financing round to fund the further development of its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) approach, which provides access to a new class of pharmacological targets that transiently appear during the process of protein folding, and to advance its proprietary pipeline programsthrough preclinical evaluation.
Skribble, the leading Swiss e-signature service, closes its third round of funding. The scale-up has secured 10 million Swiss francs as part of its Series A. The round is co-led by venture capital firms VI Partners from Switzerland and Acton from Germany. With the capital raised, Skribble aims to strengthen its position as a pioneer in existing markets and drive expansion in Europe.
VI Partners' founding team came together in 2000 to advise Venture Incubator, an investment vehicle initiated by ETHZ and funded by ten blue-chip Swiss companies. Today, we advise funds investing across Europe in tech and healthcare.